Welcome to
Cerebrolysin®

Cerebrolysin® is a multi-modal neuropeptide drug which improves the brain’s ability for self-repair by stimulating neurorecovery.
Learn more

News

CREGS Launch - Study Insights and First Expert Reactions

Watch the video to gain deeper insights into the CREGS study and its clinical relevance!
learn more

WSC 2025, Barcelona - EVER Symposium

Breakthroughs in AIS Therapy: Recent trial results in evidence-based cerebroprotection
learn more

CREGS - New stroke study available

In the CREGS study, patients treated with Cerebrolysin® showed a significant improvement in functional recovery compared with the control group, as measured by the modified Rankin Scale (mRS) and the NIH Stroke Scale (NIHSS).
Learn more

Mode
of Action

Cerebrolysin® is a multimodal drug. 3-D Videos and a well structured booklet will show you all details about its MoA.
Learn more

How to use
Cerebrolysin®

All relevant information about dosage, initiation and duration of treatment, route of administration can be found here.
Learn more

Indications

Stroke

Learn more about stroke and the different treatment options. Cerebrolysin® is an additional therapy in stroke.
Learn more

TBI

Traumatic brain injury affects approx. 15 million individuals annually worldwide. Cerebrolysin® is an add-on therapy to standard care for all these patients.
Learn more

Cognitive Impairment

A treatment approach in cognitive impairment is the use of multimodal drugs, like Cerebrolysin®.
Learn more

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.